Literature DB >> 6142928

On the possible mechanism of phenylacetate neurotoxicity: inhibition of choline acetyltransferase by phenylacetyl-CoA.

A Potempska, Y H Loo, H M Wisniewski.   

Abstract

The influence of phenylacetate, phenylbutyrate, and phenylacetyl-CoA on the activity of choline acetyltransferase and S-acetyl-CoA synthetase was investigated in vitro. Phenylacetyl-CoA was found to be a very potent inhibitor of choline acetyltransferase, competitive for acetyl-CoA with Ki of 3.1 X 10(-7)M. In contrast, millimolar concentrations of phenylacetate and phenylbutyrate were required to inhibit the activity of the enzyme. Activity of S-acetyl-CoA synthetase was affected only slightly by the three agents in concentrations of 10(-3)-10(-2)M. At this time, results are interpreted to suggest that in phenylketonuria, phenylacetate exerts its neurotoxic action through its metabolic product, phenylacetyl-CoA, which could severely decrease the availability of acetyl-CoA.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6142928     DOI: 10.1111/j.1471-4159.1984.tb02819.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  5 in total

1.  Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonaemia.

Authors:  V Praphanphoj; S A Boyadjiev; L J Waber; S W Brusilow; M T Geraghty
Journal:  J Inherit Metab Dis       Date:  2000-03       Impact factor: 4.982

Review 2.  The biochemical basis of mitochondrial diseases.

Authors:  H R Scholte
Journal:  J Bioenerg Biomembr       Date:  1988-04       Impact factor: 2.945

3.  Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.

Authors:  M Mokhtarani; G A Diaz; W Rhead; S A Berry; U Lichter-Konecki; A Feigenbaum; A Schulze; N Longo; J Bartley; W Berquist; R Gallagher; W Smith; S E McCandless; C Harding; D C Rockey; J M Vierling; P Mantry; M Ghabril; R S Brown; K Dickinson; T Moors; C Norris; D Coakley; D A Milikien; S C Nagamani; C Lemons; B Lee; B F Scharschmidt
Journal:  Mol Genet Metab       Date:  2013-10-08       Impact factor: 4.797

Review 4.  Emergency management of inherited metabolic diseases.

Authors:  V Prietsch; M Lindner; J Zschocke; W L Nyhan; G F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2002-11       Impact factor: 4.982

5.  Phenylbutyrate modulates polyamine acetylase and ameliorates Snyder-Robinson syndrome in a Drosophila model and patient cells.

Authors:  Xianzun Tao; Yi Zhu; Zoraida Diaz-Perez; Seok-Ho Yu; Jackson R Foley; Tracy Murray Stewart; Robert A Casero; Richard Steet; R Grace Zhai
Journal:  JCI Insight       Date:  2022-07-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.